The global high potency APIs market is expected to grow at a CAGR of 6.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing demand for high potency APIs in various therapeutic areas such as oncology, glaucoma, hormonal imbalance and respiratory disorders. The increasing prevalence of chronic diseases such as cancer and diabetes has led to an increase in the demand for high potency APIs which are used in these therapeutic areas.
The global high potency APIs market by type is segmented into innovative and generic drugs. The generic drugs segment accounted for a share of over 80% in 2017 owing to their low cost and availability across different geographies. However, with the introduction of new innovative drugs that are more effective than generics, there has been an increase in their adoption rates which will lead to a decline in the share held by generics over time.
-The global High Potency APIs market is expected to grow at a CAGR of 6.5% during the forecast period, 2018-2025.
-The growth of the global High Potency APIs market is driven by factors such as increasing demand for high potency APIs in emerging markets and rising demand for high potency API products in developed markets.
-Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases are driving the growth of the global High Potency APIs market.
Industry Growth Insights published a new data on “High Potency APIs (HPAPI) Market”. The research report is titled “High Potency APIs (HPAPI) Market research by Types (Innovative, Generic), By Applications (Oncology, Glaucoma, Hormonal Imbalance, Respiratory Disorders, Other), By Players/Companies Pfizer (US), Novartis (Switzerland), Sanofi (France), Roche (Switzerland), Eli Lilly and Company (US), Merck (US), AbbVie (US), Boehringer Ingelheim (Germany), GlaxoSmithKline (UK), RAG-Stiftung (Germany), Bristol-Myers Squibb (US), Teva (Israel), Mylan (US), AstraZeneca (UK), Lonza (Swiss), Ash Stevens (US), AMRI (US)”.
Scope Of The Report
Report Attributes
Report Details
Report Title
High Potency APIs (HPAPI) Market Research Report
By Type
Innovative, Generic
By Application
Oncology, Glaucoma, Hormonal Imbalance, Respiratory Disorders, Other
By Companies
Pfizer (US), Novartis (Switzerland), Sanofi (France), Roche (Switzerland), Eli Lilly and Company (US), Merck (US), AbbVie (US), Boehringer Ingelheim (Germany), GlaxoSmithKline (UK), RAG-Stiftung (Germany), Bristol-Myers Squibb (US), Teva (Israel), Mylan (US), AstraZeneca (UK), Lonza (Swiss), Ash Stevens (US), AMRI (US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global High Potency APIs (HPAPI) Market Report Segments:
The global High Potency APIs (HPAPI) market is segmented on the basis of:
Types
Innovative, Generic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Glaucoma, Hormonal Imbalance, Respiratory Disorders, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer (US)
- Novartis (Switzerland)
- Sanofi (France)
- Roche (Switzerland)
- Eli Lilly and Company (US)
- Merck (US)
- AbbVie (US)
- Boehringer Ingelheim (Germany)
- GlaxoSmithKline (UK)
- RAG-Stiftung (Germany)
- Bristol-Myers Squibb (US)
- Teva (Israel)
- Mylan (US)
- AstraZeneca (UK)
- Lonza (Swiss)
- Ash Stevens (US)
- AMRI (US)
 Market Overview.svg)
Highlights of The High Potency APIs (HPAPI) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Innovative
- Generic
- By Application:
- Oncology
- Glaucoma
- Hormonal Imbalance
- Respiratory Disorders
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the High Potency APIs (HPAPI) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HPAPI is a term used to describe APIs that offer increased performance over traditional APIs. HPAPI can refer to any API that offers faster response times, more efficient use of bandwidth, or improved reliability.
Some of the major players in the high potency apis (hpapi) market are Pfizer (US), Novartis (Switzerland), Sanofi (France), Roche (Switzerland), Eli Lilly and Company (US), Merck (US), AbbVie (US), Boehringer Ingelheim (Germany), GlaxoSmithKline (UK), RAG-Stiftung (Germany), Bristol-Myers Squibb (US), Teva (Israel), Mylan (US), AstraZeneca (UK), Lonza (Swiss), Ash Stevens (US), AMRI (US).
The high potency apis (hpapi) market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. High Potency APIs (HPAPI) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. High Potency APIs (HPAPI) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. High Potency APIs (HPAPI) Market - Supply Chain
4.5. Global High Potency APIs (HPAPI) Market Forecast
4.5.1. High Potency APIs (HPAPI) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. High Potency APIs (HPAPI) Market Size (000 Units) and Y-o-Y Growth
4.5.3. High Potency APIs (HPAPI) Market Absolute $ Opportunity
5. Global High Potency APIs (HPAPI) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
5.3.1. Innovative
5.3.2. Generic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global High Potency APIs (HPAPI) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Glaucoma
6.3.3. Hormonal Imbalance
6.3.4. Respiratory Disorders
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global High Potency APIs (HPAPI) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. High Potency APIs (HPAPI) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global High Potency APIs (HPAPI) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. High Potency APIs (HPAPI) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global High Potency APIs (HPAPI) Demand Share Forecast, 2019-2026
9. North America High Potency APIs (HPAPI) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America High Potency APIs (HPAPI) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Glaucoma
9.4.3. Hormonal Imbalance
9.4.4. Respiratory Disorders
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
9.7.1. Innovative
9.7.2. Generic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America High Potency APIs (HPAPI) Demand Share Forecast, 2019-2026
10. Latin America High Potency APIs (HPAPI) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America High Potency APIs (HPAPI) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Glaucoma
10.4.3. Hormonal Imbalance
10.4.4. Respiratory Disorders
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
10.7.1. Innovative
10.7.2. Generic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America High Potency APIs (HPAPI) Demand Share Forecast, 2019-2026
11. Europe High Potency APIs (HPAPI) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe High Potency APIs (HPAPI) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Glaucoma
11.4.3. Hormonal Imbalance
11.4.4. Respiratory Disorders
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
11.7.1. Innovative
11.7.2. Generic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe High Potency APIs (HPAPI) Demand Share, 2019-2026
12. Asia Pacific High Potency APIs (HPAPI) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific High Potency APIs (HPAPI) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Glaucoma
12.4.3. Hormonal Imbalance
12.4.4. Respiratory Disorders
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
12.7.1. Innovative
12.7.2. Generic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific High Potency APIs (HPAPI) Demand Share, 2019-2026
13. Middle East & Africa High Potency APIs (HPAPI) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa High Potency APIs (HPAPI) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa High Potency APIs (HPAPI) Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Glaucoma
13.4.3. Hormonal Imbalance
13.4.4. Respiratory Disorders
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa High Potency APIs (HPAPI) Market Size and Volume Forecast by Type
13.7.1. Innovative
13.7.2. Generic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa High Potency APIs (HPAPI) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global High Potency APIs (HPAPI) Market: Market Share Analysis
14.2. High Potency APIs (HPAPI) Distributors and Customers
14.3. High Potency APIs (HPAPI) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer (US)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis (Switzerland)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi (France)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche (Switzerland)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly and Company (US)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck (US)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AbbVie (US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Boehringer Ingelheim (Germany)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline (UK)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. RAG-Stiftung (Germany)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bristol-Myers Squibb (US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Teva (Israel)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Mylan (US)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. AstraZeneca (UK)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Lonza (Swiss)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Ash Stevens (US)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. AMRI (US)
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
